Bioheng Therapeutics Receives FDA RPDD for Off‑The‑Shelf CAR‑T CTD402
Bioheng Therapeutics (China) announced that the U.S. Food and Drug Administration (FDA) has granted Rare...
Drug
Fosun Pharma Secures China Rights to Accropeutics’ AC‑201 JAK Inhibitor
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that it has...
Shenlian Bio Launches Phase 2 Trial for UB‑221 Injection in Chronic Urticaria
Shanghai Shenlian Biomedical Co., Ltd. (Shenlian Bio, SHA: 688098) announced that its licensed innovative drug,...
Mabwell’s 9MW3811 Receives NMPA Phase II Approval for Pathological Scar Treatment
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced on September 1 that the National Medical...
Suzhou Zelgen Secures FDA Approval for Dual‑Targeted Therapy Trial in Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the U.S. Food and Drug Administration...
Mabwell Secures First Overseas Approval for Denosumab Biosimilars in Pakistan
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that the Drug Regulatory Authority of Pakistan...
Novo Nordisk’s STEER Study: Wegovy Cuts Cardiovascular Risk 57 % vs. Tirzepatide
Danish biopharmaceutical giant Novo Nordisk A/S (NYSE: NVO) presented compelling real‑world evidence from the STEER...
Eisai & Biogen Secure FDA Approval for Lecanemab Auto‑Injector – Home‑Based Alzheimer’s Therapy
Japan-based Eisai (TYO: 4523) and US-based Biogen (NASDAQ: BIIB) announced that the U.S. Food and...
Suzhou HemaCell Receives NMPA IND Approval for First‑In‑Class Megakaryocyte Injection – Thrombocytopenia Treatment
Suzhou HemaCell Therapeutics, a platelet‑regeneration‑focused cell‑therapy developer, announced that the Center for Drug Evaluation (CDE)...
Boehringer Ingelheim & Sino Biopharma Secure Conditional Approval for Zongertinib in China
In a joint announcement, Boehringer Ingelheim (BI) and Sino Biopharmaceutical Limited (HKG: 1177) confirmed that the...
Santen Receives Boao Lecheng Approval for RYJUSEA – A Preservative‑Free Atropine Eye Drop for Pediatric Myopia
Japan‑based Santen Pharmaceutical Co., Ltd. (TYO: 4536) announced that its RYJUSEA (atropine sulfate hydrate) has...
RemeGen’s Telitacicept Hits Primary Endpoint in Phase III IgA Nephropathy Trial
China‑based RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) on Aug, 27, 2025announced that its first‑in‑class BLyS/APRIL...
Changchun High Files GenSci134 Clinical Trial for Growth Hormone Deficiency
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) on Aug 27, 2025 disclosed...
Regeneron’s Cemdisiran Beats Key Milestones in Phase III gMG Trial
US-based Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) on Aug 27, 2025 disclosed that its investigational monotherapy, cemdisiran,...
Gilead’s Yeytuo Gains EU Marketing Authorization for Twice‑Yearly HIV‑1 PrEP
European Commission Grant – On 26 Aug 2025 Gilead Sciences (NASDAQ: GILD) announced that the European Commission...
Innogen Commences Phase II Trial of Efsubaglutide Alfa for Obesity in Australia
Shanghai Innogen Pharmaceutical Technology Co., Ltd. (HKG: 2591) announced on 26 August, 2025 that the first...
Humanwell Secures NMPA Approval for Remimazolam ICU Sedation
China‑based Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that the National Medical Products Administration...
Eisai & Biogen Launch Lecanemab in Austria & Germany – First Cause‑Based Alzheimer’s Therapy
Japan-based Eisai (TYO: 4523) and US-based Biogen (NASDAQ: BIIB) have officially launched Lecanemab (LEQEMBI)—the first...
Anke Biotech Secures Long‑Acting FSH‑CTP Approval in China
Shanghai Bao Pharmaceuticals Co., Ltd. has received official marketing authorization from China’s National Medical Products Administration (NMPA)...
Hengrui Pharmaceuticals Secures NMPA Approval for HRS‑2162 and HRS‑6093 Clinical Trials
China‑based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that its two investigational...